Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is a Healthcare company (Biotechnology) with a market capitalization of $260M. The Maz Rating grades it against the other companies in its sector.
Enanta Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $8.93, Enanta Pharmaceuticals, Inc. trades at 4.9x sales and 3.9x book value. Over the last twelve months it generated about $53M of revenue and a net loss of $50M. It runs a gross margin of -84.4%, an operating margin of -99.0% and a net margin of -108.3%. It shows return on equity of -64.3%, return on invested capital of -27.6% and a free cash flow yield of -11.9%. On the balance sheet: a debt-to-equity ratio of 0.68 and a current ratio of 3.78. Over the past 52 weeks the share price ranged from $8.81 to $17.15, with a beta of 0.96.
Enanta Pharmaceuticals, Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 14 Buy, 3 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Enanta Pharmaceuticals, Inc. (ENTA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 15.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 54.6% / 30% · Interest income / Revenue 14.1% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 15.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 54.6% / 33% · Receivables / Mkt Cap (36m) 1.64% / 49% · Interest income / Revenue 14.1% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 15.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 54.6% / 33.33% · Receivables / Mkt Cap (24m) 1.64% / 33.33% · Interest income / Revenue 14.1% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 26.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 60.3% / 33.33% · Receivables / Avg Assets (4Q) 2.36% / 33.33% · Interest income / Revenue 14.1% / 5% | Fail |
| FTSE | Debt / Total Assets 19.9% / 33.33% · (Cash+ST Inv) / Total Assets 70.6% / 33.33% · (Cash+Recv) / Total Assets 72.7% / 33.33% · Interest income / Revenue 14.1% / 5% | Fail |
No. As of September 2026, Enanta Pharmaceuticals, Inc. (ENTA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Enanta Pharmaceuticals, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 14.1% of each dividend: Enanta Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q4 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.